NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

Inability to produce enough units of vaccine to give timely doses to the patients would be a mandatory reporting issue, wouldn't it?

This might not be true in a blinded trial where the shareholder's interest in having the trial considered valid by the FDA outweighs their interest of being informed of such a development.

But in a non-blinded trial where there is no restriction on releasing material information on a problem that is adversely impacting the company's ability to conduct effective trials so that they would be legally obliged to report it and would have no legitimate reason to withhold it.

For this reason alone, I think you're wrong about this issue.